XKRX214390
Market cap114mUSD
Jan 09, Last price
6,910.00KRW
1D
0.00%
Jan 2017
-50.18%
IPO
-78.28%
Name
Kyongbo Pharmaceutical Co Ltd
Chart & Performance
Profile
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients in South Korea. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also exports its products to 30 countries worldwide. The company was formerly known as Kyongbo Chemical Co. Ltd. and changed its name to Kyongbo Pharmaceutical Co., Ltd in March 2002. Kyongbo Pharmaceutical Co., Ltd was founded in 1987 and is headquartered in Asan, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 216,357,482 10.24% | 196,264,902 15.00% | |||||||
Cost of revenue | 192,719,295 | 178,960,338 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 23,638,187 | 17,304,564 | |||||||
NOPBT Margin | 10.93% | 8.82% | |||||||
Operating Taxes | (802,476) | (1,225,426) | |||||||
Tax Rate | |||||||||
NOPAT | 24,440,663 | 18,529,991 | |||||||
Net income | 2,974,400 387.14% | 610,590 -108.15% | |||||||
Dividends | (1,195,343) | (1,195,343) | |||||||
Dividend yield | 0.60% | 0.50% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 74,262,254 | 64,270,589 | |||||||
Long-term debt | 4,380,675 | 628,754 | |||||||
Deferred revenue | (2,349,180) | ||||||||
Other long-term liabilities | 1,988,291 | 1,030,299 | |||||||
Net debt | 59,619,585 | 45,736,094 | |||||||
Cash flow | |||||||||
Cash from operating activities | 4,844,320 | 10,126,731 | |||||||
CAPEX | (10,877,137) | (13,183,820) | |||||||
Cash from investing activities | (14,267,871) | (14,877,198) | |||||||
Cash from financing activities | 7,159,152 | 6,588,722 | |||||||
FCF | 13,420,225 | 16,652,476 | |||||||
Balance | |||||||||
Cash | 5,347,057 | 7,218,480 | |||||||
Long term investments | 13,676,287 | 11,944,769 | |||||||
Excess cash | 8,205,469 | 9,350,003 | |||||||
Stockholders' equity | 107,986,000 | 108,640,458 | |||||||
Invested Capital | 214,100,540 | 197,381,059 | |||||||
ROIC | 11.88% | 9.57% | |||||||
ROCE | 10.63% | 8.28% | |||||||
EV | |||||||||
Common stock shares outstanding | 23,907 | 23,907 | |||||||
Price | 8,390.00 -16.10% | 10,000.00 -6.98% | |||||||
Market cap | 200,578,555 -16.10% | 239,068,600 -6.98% | |||||||
EV | 260,198,141 | 284,804,694 | |||||||
EBITDA | 35,337,007 | 29,240,300 | |||||||
EV/EBITDA | 7.36 | 9.74 | |||||||
Interest | 3,400,954 | 1,671,078 | |||||||
Interest/NOPBT | 14.39% | 9.66% |